Phase III trial of empagliflozin in adults with heart failure and reduced ejection fraction meets primary endpoint
In the EMPEROR-Reduced Phase III trial, empagliflozin was superior to placebo in decreasing the risk of a composite primary endpoint of cardiovascular death or hospitalisation from heart failure when added to standard of care (results to be presented at ESC Congress in August).
Source:
Biospace Inc.